Today (2017 C.E. - 2025 C.E.)

This archive spans the years 2017 through 2025, a period marked by rapid advances in clean energy, medicine, technology, and social equity. It collects documented breakthroughs, policy wins, and scientific achievements from the present era. If you want evidence that progress is real and ongoing, this is where to look.

Micro X-ray of mushrooms with false colors, for article on psilocybin clinical trials

First European psychedelic drug trial clinic opens in the U.K.

Clerkenwell Health’s opening marks a turning point for psychedelic medicine, moving it from university labs into dedicated commercial infrastructure built to carry promising compounds through late-stage clinical trials. The clinic’s first focus is patients facing terminal diagnoses — a population where conventional treatments often fall short, and where earlier psilocybin studies showed lasting reductions in anxiety and depression after just one or two sessions. By serving multiple drug developers at once, the facility could meaningfully accelerate how quickly different psychedelic compounds reach the people who need them. It’s a signal that this field is ready to scale.

Baby sleeping, for article on SIDS biomarker

Landmark study finds first biomarker to detect babies at risk of SIDS

SIDS has resisted explanation for generations, but researchers have now found the first biological signal present at birth that distinguishes vulnerable infants from others. Australian scientists discovered that babies who died of SIDS had measurably lower levels of an enzyme called butyrylcholinesterase — which helps regulate the brain’s arousal response — in routine newborn blood samples. That same heel-prick screening already happens in hospitals worldwide, meaning a future test could fit into existing programs with little disruption. This finding gives researchers a concrete target for the first time, and brings the dream of preventing these devastating losses meaningfully closer.